$287.24
8.112.91%
At Close: -
$287.24
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Madrigal Pharmaceuticals
MDGLNASDAQ
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Insider Trading Activity
Madrigal Pharmaceuticals: Insider buying and selling updated today.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Madrigal Pharmaceuticals Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
- On May 23, 2024, Robert Waltermire, the company's SENIOR VP, CHIEF PHARMA DEV. sold 1.04K shares for $231.34 each.
Ownership Statistics for Madrigal Pharmaceuticals Inc
Institutional Shares Held
11.866M
Institutional Percentage Held
55.7%
| Jun 18, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $183.55 | -$366.53K | SELL-OPTIONS | 0.00% | 5.50K | Jun 14 | View |
| Jun 14, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $186.46 | -$394.16K | SELL-OPTIONS | 0.00% | 5.50K | Jun 12 | View |
| May 23, 2024 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | -1.04K | $231.34 | -$239.67K | SELL | -15.85% | 5.50K | May 21 | View |
| May 16, 2024 | FRED CRAVES | — | 0.00 | $157.95 | -$2.47M | SELL-OPTIONS | 0.00% | 431.36K | May 14 | View |
| Apr 10, 2024 | Rebecca Taub | PRES., R&D, AND CMO | 0.00 | $127.72 | -$632.97K | SELL-OPTIONS | 0.00% | 1.11M | Apr 08 | View |
| Apr 10, 2024 | PAUL FRIEDMAN | — | 0.00 | $127.82 | -$6.22M | SELL-OPTIONS | 0.00% | 841.27K | Apr 08 | View |
| Apr 05, 2024 | Rebecca Taub | PRES., R&D, AND CMO | 0.00 | $126.68 | -$17.32M | SELL-OPTIONS | 0.00% | 1.11M | Apr 03 - Apr 05 | View |
| Apr 05, 2024 | PAUL FRIEDMAN | DIRECTOR | 0.00 | $126.69 | -$17.29M | SELL-OPTIONS | 0.00% | 841.27K | Apr 03 - Apr 05 | View |
| Apr 03, 2024 | Richard Levy | — | 0.00 | $160.70 | -$2.13M | SELL-OPTIONS | 0.00% | 10.30K | Apr 01 | View |
| Apr 03, 2024 | KENNETH BATE | DIRECTOR | 0.00 | $163.54 | -$5.80M | SELL-OPTIONS | 0.00% | 1.20K | Apr 01 - Apr 02 | View |
| Apr 03, 2024 | James Daly | DIRECTOR | 0.00 | $177.60 | -$4.90M | SELL-OPTIONS | 0.00% | 1.20K | Apr 01 - Apr 02 | View |
| Dec 18, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $161.71 | -$590.32K | SELL-OPTIONS | 0.00% | 5.67K | Dec 14 - Dec 15 | View |
| Dec 14, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 101.79K | $221.20 | $22.52M | BUY | 6.02% | 1.79M | Dec 13 - Dec 14 | View |
| Dec 14, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 34.58K | $218.31 | $7.55M | BUY | 2.08% | 1.70M | Dec 12 | View |
| Dec 14, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $155.37 | -$512.60K | SELL-OPTIONS | 0.00% | 5.67K | Dec 12 - Dec 13 | View |
| Dec 06, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $152.58 | -$388.11K | SELL-OPTIONS | 0.00% | 15.53K | Dec 04 - Dec 05 | View |
| Dec 01, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $137.62 | -$894.23K | SELL-OPTIONS | 0.00% | 15.53K | Nov 29 - Nov 30 | View |
| Nov 21, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 64.35K | $188.47 | $12.13M | BUY | 4.01% | 1.67M | Nov 21 | View |
| Nov 21, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 67.08K | $178.11 | $11.95M | BUY | 4.35% | 1.61M | Nov 17 - Nov 20 | View |
| Nov 15, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 49.39K | $158.13 | $7.81M | BUY | 3.30% | 1.55M | Nov 14 - Nov 15 | View |
| Nov 15, 2023 | BAKER BROS ADVISORS LP LPJULIAN BAKERFELIX BAKERBaker Bros Advisors GP LLCBaker Brothers Life Sciences LP | DIRECTOR | 107.50K | $146.99 | $15.80M | BUY | 7.72% | 1.50M | Nov 13 - Nov 14 | View |
| Mar 02, 2023 | Robert Waltermire | SENIOR VP, CHIEF PHARMA DEV. | 0.00 | $180.58 | -$1.85M | SELL-OPTIONS | 0.00% | 5.67K | Feb 28 - Mar 01 | View |
| Jan 19, 2023 | Richard Levy | DIRECTOR | 0.00 | $198.09 | -$4.28M | SELL-OPTIONS | 0.00% | 9.10K | Jan 17 | View |
| Jan 06, 2023 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $187.36 | -$2.48M | SELL-OPTIONS | 0.00% | 530.00 | Jan 03 | View |
| Dec 28, 2022 | Brian J. Lynch | SVP AND GENERAL COUNSEL | 0.00 | $182.98 | -$1.28M | SELL-OPTIONS | 0.00% | 530.00 | Dec 23 | View |
| Dec 28, 2022 | Remy Sukhija | CHIEF COMMERCIAL OFFICER | 0.00 | $167.20 | -$6.42M | SELL-OPTIONS | 0.00% | 0.00 | Dec 23 | View |
| Aug 19, 2020 | BAY CITY CAPITAL LLCBay City Capital Management IV LLCBay City Capital Fund IV LPBAY CITY CAPITAL FUND IV CO INVESMENT FUND LP | — | -30.00K | $109.74 | -$3.29M | SELL | -19.45% | 124.25K | Aug 17 - Aug 19 | View |
| Aug 19, 2020 | Fred B Craves | — | -30.00K | $109.74 | -$3.29M | SELL | -18.42% | 132.88K | Aug 17 - Aug 19 | View |
| Feb 26, 2020 | David Milligan | — | -10.00K | $131.60 | -$1.32M | SELL | -33.33% | 20.00K | Nov 19 | View |
| Feb 26, 2020 | s/ David Milligan | — | -20.00K | $112.54 | -$2.25M | SELL | -100.00% | 0.00 | Nov 21 | View |
| Dec 13, 2019 | BAY CITY CAPITAL LLCBay City Capital Management IV LLCBay City Capital Fund IV LPBAY CITY CAPITAL FUND IV CO INVESMENT FUND LP | 10% OWNER | -1.20M | $105.47 | -$126.56M | SELL | -93.16% | 88.15K | Dec 13 | View |
| Dec 13, 2019 | Fred B Craves | DIRECTOR | -1.20M | $105.47 | -$126.56M | SELL | -93.16% | 88.15K | Dec 13 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.